Prolongation of coronavirus outbreak in China could hit Indian pharma sector
China accounted for 67.56 per cent of total imports of bulk drugs and
drug intermediates in 2018-19 at USD 2,405.42 million. "The situation
is being closely monitored by all companies. The government is seized
of the issue and all are working in an integrated way to deal with the
situation." Indian Pharmaceutical Alliance (IPA) Secretary General
Sudarshan Jain told PTI.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/prolongation-of-coronavirus-outbreak-in-china-could-hit-indian-pharma-sector/articleshow/74040748.cms
drug intermediates in 2018-19 at USD 2,405.42 million. "The situation
is being closely monitored by all companies. The government is seized
of the issue and all are working in an integrated way to deal with the
situation." Indian Pharmaceutical Alliance (IPA) Secretary General
Sudarshan Jain told PTI.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/prolongation-of-coronavirus-outbreak-in-china-could-hit-indian-pharma-sector/articleshow/74040748.cms
The major portion of Pharma Exports from India include intermediates, biologicals, herbal products, drug formulations, surgicals and bulk drugs. In 2019, India did exceptionally well, generating around 1.3 trillion rupees on pharmaceutical export. These growing records initiated many foreign investments & key M&A deals to scale the annual production rate. To envision the plan, government bodies designed various policies like Ayushman Bharat Yojana; backing the idea of employment & economic growth.
ReplyDelete